Pure Global
NCT06285019

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

Efficacy and Safety of Modified Hepatic Artery Infusion Chemotherapy (TOMOX-HAIC) in Combination With Sintilimab and Bevacizumab Biosimilar for the First-line Treatment of Advanced Hepatocellular Carcinoma: a Prospective, Single-arm, Phase II Clinical Study
Fudan University·Phase 2·ClinicalTrials.gov·procedureRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
TOMOX-HAIC
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2023
End date
Dec 31, 2025
Enrollment
65 participants
Primary outcome

objective response rate (ORR)

Summary

This is a single-center, single-arm, phase II clinical study, to explore the efficacy and
 safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first
 line treatment in patients with advanced hepatocellular carcinoma.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06285019
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06285019 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 65 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.